Who owns Jade Biosciences, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of JBIO from SEC Form 13F filings across 154 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 154 institutions disclosed 72.9M shares of Jade Biosciences, Inc. worth $1.62B — about 119.4% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
154
13F holders
$1.62B
value, 2026 filers
119.4%
of shares outstanding (72.9M sh)
52
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of JBIO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.1M | $202.8M | 0.0% | 14.9% | +28.8% |
| 2 | Jupiter Topco LLCNEW | 6.3M | $139.4M | 0.1% | 10.3% | new |
| 3 | Fairmount Funds Management LLC | 4.6M | $101.2M | 6.7% | 7.5% | 0.0% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 3.7M | $81.6M | 0.7% | 6% | 0.0% |
| 5 | Venrock Adviser, LLC | 3.2M | $71.6M | 2.2% | 5.3% | 0.0% |
| 6 | Bellevue Group AG | 3.1M | $67.9M | 1.4% | 5% | -12.7% |
| 7 | Paradigm Biocapital Advisors LPNEW | 2.9M | $63.5M | 1.2% | 4.7% | new |
| 8 | BlackRock, Inc. | 2.8M | $62.2M | 0.0% | 4.6% | +21.1% |
| 9 | FRANKLIN RESOURCES INCNEW | 2.8M | $62.0M | 0.0% | 4.6% | new |
| 10 | STATE STREET CORP | 2.3M | $51.9M | 0.0% | 3.8% | +256.2% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $49.9M | 0.0% | 3.7% | +24.9% |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 1.9M | $42.5M | 0.1% | 3.1% | new |
| 13 | Polar Capital Holdings PlcNEW | 1.8M | $41.0M | 0.1% | 3% | new |
| 14 | Avidity Partners Management LP | 1.7M | $37.8M | 6.1% | 2.8% | +21.4% |
| 15 | Remedium Capital Partners, LLC | 1.6M | $35.1M | 7.8% | 2.6% | 0.0% |
| 16 | Soleus Capital Management, L.P. | 1.6M | $34.5M | 1.2% | 2.5% | +94.6% |
| 17 | JPMORGAN CHASE & CO | 1.5M | $32.6M | 0.0% | 2.4% | +9198.9% |
| 18 | BAKER BROS. ADVISORS LP | 1.2M | $27.3M | 0.1% | 2% | -25.0% |
| 19 | Logos Global Management LP | 1.1M | $25.0M | 1.1% | 1.8% | +181.3% |
| 20 | Versant Venture Management, LLC | 991,783 | $22.0M | 13.6% | 1.6% | -35.0% |
| 21 | ACORN CAPITAL ADVISORS, LLC | 986,760 | $21.9M | 6.0% | 1.6% | +25.4% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 985,178 | $21.9M | 0.0% | 1.6% | +19.8% |
| 23 | CITADEL ADVISORS LLC | 929,407 | $20.7M | 0.0% | 1.5% | +577.3% |
| 24 | Foresite Capital Management VI LLC | 886,667 | $19.7M | 3.1% | 1.5% | +177.1% |
| 25 | Balyasny Asset Management L.P. | 878,726 | $19.5M | 0.0% | 1.4% | +118.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.